BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 19840520)

  • 1. Neuroblastoma: biology and staging.
    Mueller S; Matthay KK
    Curr Oncol Rep; 2009 Nov; 11(6):431-8. PubMed ID: 19840520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable
    Ambros IM; Tonini GP; Pötschger U; Gross N; Mosseri V; Beiske K; Berbegall AP; Bénard J; Bown N; Caron H; Combaret V; Couturier J; Defferrari R; Delattre O; Jeison M; Kogner P; Lunec J; Marques B; Martinsson T; Mazzocco K; Noguera R; Schleiermacher G; Valent A; Van Roy N; Villamon E; Janousek D; Pribill I; Glogova E; Attiyeh EF; Hogarty MD; Monclair TF; Holmes K; Valteau-Couanet D; Castel V; Tweddle DA; Park JR; Cohn S; Ladenstein R; Beck-Popovic M; De Bernardi B; Michon J; Pearson ADJ; Ambros PF
    J Clin Oncol; 2020 Nov; 38(31):3685-3697. PubMed ID: 32903140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
    Thompson D; Vo KT; London WB; Fischer M; Ambros PF; Nakagawara A; Brodeur GM; Matthay KK; DuBois SG
    Cancer; 2016 Mar; 122(6):935-45. PubMed ID: 26709890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations.
    Spitz R; Hero B; Westermann F; Ernestus K; Schwab M; Berthold F
    Genes Chromosomes Cancer; 2002 Jul; 34(3):299-305. PubMed ID: 12007190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene.
    Carén H; Erichsen J; Olsson L; Enerbäck C; Sjöberg RM; Abrahamsson J; Kogner P; Martinsson T
    BMC Genomics; 2008 Jul; 9():353. PubMed ID: 18664255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
    Caron H; van Sluis P; de Kraker J; Bökkerink J; Egeler M; Laureys G; Slater R; Westerveld A; Voûte PA; Versteeg R
    N Engl J Med; 1996 Jan; 334(4):225-30. PubMed ID: 8531999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q.
    Boensch M; Oberthuer A; Fischer M; Skowron M; Oestreich J; Berthold F; Spitz R
    Diagn Mol Pathol; 2005 Sep; 14(3):177-82. PubMed ID: 16106200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification.
    Plantaz D; Vandesompele J; Van Roy N; Lastowska M; Bown N; Combaret V; Favrot MC; Delattre O; Michon J; Bénard J; Hartmann O; Nicholson JC; Ross FM; Brinkschmidt C; Laureys G; Caron H; Matthay KK; Feuerstein BG; Speleman F
    Int J Cancer; 2001 Mar; 91(5):680-6. PubMed ID: 11267980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there?
    Vandesompele J; Speleman F; Van Roy N; Laureys G; Brinskchmidt C; Christiansen H; Lampert F; Lastowska M; Bown N; Pearson A; Nicholson JC; Ross F; Combaret V; Delattre O; Feuerstein BG; Plantaz D
    Med Pediatr Oncol; 2001 Jan; 36(1):5-10. PubMed ID: 11464905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical investigation of neuroblastoma with partial deletion in the short arm of chromosome 1.
    Ohtsu K; Hiyama E; Ichikawa T; Matsuura Y; Yokoyama T
    Clin Cancer Res; 1997 Jul; 3(7):1221-8. PubMed ID: 9815803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allelotype of neuroblastoma.
    Takita J; Hayashi Y; Kohno T; Shiseki M; Yamaguchi N; Hanada R; Yamamoto K; Yokota J
    Oncogene; 1995 Nov; 11(9):1829-34. PubMed ID: 7478611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of chromosome 1p loss of heterozygosity in neuroblastoma.
    Maris JM; White PS; Beltinger CP; Sulman EP; Castleberry RP; Shuster JJ; Look AT; Brodeur GM
    Cancer Res; 1995 Oct; 55(20):4664-9. PubMed ID: 7553646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.
    Simon T; Spitz R; Faldum A; Hero B; Berthold F
    J Pediatr Hematol Oncol; 2004 Dec; 26(12):791-6. PubMed ID: 15591897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroblastoma in adolescents: genetic and clinical characterisation.
    Castel V; Villamón E; Cañete A; Navarro S; Ruiz A; Melero C; Herrero A; Yáñez Y; Noguera R
    Clin Transl Oncol; 2010 Jan; 12(1):49-54. PubMed ID: 20080471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.
    Owens C; Irwin M
    Crit Rev Clin Lab Sci; 2012; 49(3):85-115. PubMed ID: 22646747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.
    Depuydt P; Boeva V; Hocking TD; Cannoodt R; Ambros IM; Ambros PF; Asgharzadeh S; Attiyeh EF; Combaret V; Defferrari R; Fischer M; Hero B; Hogarty MD; Irwin MS; Koster J; Kreissman S; Ladenstein R; Lapouble E; Laureys G; London WB; Mazzocco K; Nakagawara A; Noguera R; Ohira M; Park JR; Pötschger U; Theissen J; Tonini GP; Valteau-Couanet D; Varesio L; Versteeg R; Speleman F; Maris JM; Schleiermacher G; De Preter K
    J Natl Cancer Inst; 2018 Oct; 110(10):1084-1093. PubMed ID: 29514301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma.
    Spitz R; Betts DR; Simon T; Boensch M; Oestreich J; Niggli FK; Ernestus K; Berthold F; Hero B
    Cancer Genet Cytogenet; 2006 May; 167(1):51-6. PubMed ID: 16682287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.
    Berbegall AP; Villamón E; Piqueras M; Tadeo I; Djos A; Ambros PF; Martinsson T; Ambros IM; Cañete A; Castel V; Navarro S; Noguera R
    Oncogene; 2016 Mar; 35(11):1423-32. PubMed ID: 26119945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.